The FDA's Breakthrough Therapy Designation is designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s). This could potentially lead to faster approval and commercialization of Felzartamab, which would be beneficial for I-Mab.